Erlotinib: Difference between revisions
David Canner (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size=" | <applet load="" size="350" color="" frame="true" spin="on" Scene ="Erlotinib/Erlotinib/1" align="right" caption="Erlotinib, also known as Tarceva"/> | ||
===Better Known as: Tarceva=== | ===Better Known as: Tarceva=== | ||
* Marketed By: Genentech, OSI Pharmaceutials, & Roche | * Marketed By: Genentech, OSI Pharmaceutials, & Roche | ||
* Major Indication: Pancreatic & Small | * Major Indication: Pancreatic & Small Cell Lung [[Cancer]] | ||
* Drug Class: [[EGFR]] Inhibitor | * Drug Class: [[EGFR]] Inhibitor | ||
* Date of FDA Approval (Expiration): 2005 (2020) | * Date of FDA Approval (Expiration): 2005 (2020) | ||